Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

356 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study.
Gianotti N, Poli A, Galli M, Pan A, Rizzardini G, Soria A, Viale P, Di Biagio A, Quirino T, Viganò P, Bonfanti P, d'Arminio Monforte A, Fortino I, Lazzarin A. Gianotti N, et al. Among authors: bonfanti p. New Microbiol. 2014 Oct;37(4):439-48. Epub 2014 Oct 1. New Microbiol. 2014. PMID: 25387282 Free article. Clinical Trial.
Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy.
Bandera A, Gori A, Sabbatini F, Madeddu G, Bonora S, Libertone R, Mastroianni C, Bonfanti P, d'Arminio Monforte A, Cozzi-Lepri A; Icona Foundation Study Group. Bandera A, et al. Among authors: bonfanti p. PLoS One. 2015 May 1;10(5):e0124252. doi: 10.1371/journal.pone.0124252. eCollection 2015. PLoS One. 2015. PMID: 25933346 Free PMC article.
Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?
Taramasso L, Ricci E, Celesia BM, Bonfanti P, Quirino T, Squillace N, Nicolini LA, Maggi P, Martinelli C, De Socio GV, Di Biagio A; on behalf CISAI Study Group. Taramasso L, et al. Among authors: bonfanti p. Clin Res Hepatol Gastroenterol. 2017 Oct;41(5):e76-e79. doi: 10.1016/j.clinre.2017.03.006. Epub 2017 Apr 21. Clin Res Hepatol Gastroenterol. 2017. PMID: 28438572 No abstract available.
Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.
Squillace N, Ricci E, Quirino T, Gori A, Bandera A, Carenzi L, De Socio GV, Orofino G, Martinelli C, Madeddu G, Rusconi S, Maggi P, Celesia BM, Cordier L, Vichi F, Calza L, Falasca K, Di Biagio A, Pellicanò GF, Bonfanti P; CISAI Study Group. Squillace N, et al. Among authors: bonfanti p. PLoS One. 2017 Jun 20;12(6):e0179254. doi: 10.1371/journal.pone.0179254. eCollection 2017. PLoS One. 2017. PMID: 28632758 Free PMC article.
Weight Gain: A Possible Side Effect of All Antiretrovirals.
Taramasso L, Ricci E, Menzaghi B, Orofino G, Passerini S, Madeddu G, Martinelli CV, De Socio GV, Squillace N, Rusconi S, Bonfanti P, Di Biagio A; CISAI Study Group. Taramasso L, et al. Among authors: bonfanti p. Open Forum Infect Dis. 2017 Nov 3;4(4):ofx239. doi: 10.1093/ofid/ofx239. eCollection 2017 Fall. Open Forum Infect Dis. 2017. PMID: 29255735 Free PMC article.
Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project.
Bagella P, De Socio GV, Ricci E, Menzaghi B, Martinelli C, Squillace N, Maggi P, Orofino G, Calza L, Carenzi L, Celesia BM, Penco G, Di Biagio A, Valsecchi L, Vichi F, Colombo V, Parruti G, Dentone C, Falasca K, Bonfanti P, Madeddu G; C.I.S.A.I. Study Group, Italy. Bagella P, et al. Among authors: bonfanti p. Infect Drug Resist. 2018 Apr 26;11:615-623. doi: 10.2147/IDR.S152090. eCollection 2018. Infect Drug Resist. 2018. PMID: 29731650 Free PMC article.
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).
Taramasso L, Tatarelli P, Ricci E, Madeddu G, Menzaghi B, Squillace N, De Socio GV, Martinelli C, Gulminetti R, Maggi P, Orofino G, Vichi F, Di Biagio A, Bonfanti P; CISAI Study Group. Taramasso L, et al. Among authors: bonfanti p. BMC Infect Dis. 2018 Jul 31;18(1):357. doi: 10.1186/s12879-018-3268-5. BMC Infect Dis. 2018. PMID: 30064371 Free PMC article.
356 results